Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2371 to 2385 of 8314 results

  1. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]

    In development Reference number: GID-HST10061 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    In development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    In development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dupilumab for treating bullous pemphigoid [ID6479]

    In development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    In development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development

  9. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  11. Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids

    Awaiting development Reference number: GID-IPG10465 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  12. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Needle Muscle Biopsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Sentinel Node Biopsy approved for pathological staging of clinically T1-T2 N0 oral cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

    In development Reference number: GID-TA11333 Expected publication date: TBC

    Technology appraisal guidance
    In development